Recent advances in genetics, diagnostics and imaging have progressed scientists’ understanding of what causes a large number of neurodegenerative diseases. Many of these scientists reside within the greater south east of England, and the region has both breadth and depth in terms of neuroscience research. Turning progress in basic science into effective treatments still remains the challenge; however collaborative efforts will prove vital in ensuring scientific developments translate into improved patient care.

The ‘Golden Triangle’ is the world-leading life sciences cluster of Cambridge, London and Oxford, sitting at the heart of England’s greater south east. This cluster is home to cutting-edge scientific research and ground-breaking medical innovations, which benefit not only the surrounding communities but also has a global impact. With some of the oldest and most prestigious universities in the world and five out of the seven academic health sciences centres in the UK, this region is uniquely located to stimulate collaboration and turn discoveries into pioneering medical treatments, therapies and technological developments. New research centres in the area, such as The Francis Crick Institute, The Alan Turing Institute and the Translation & Innovation Hub at Imperial White City Campus, complement the thriving life sciences ecosystem, and aim to accelerate the translation of lab-based research into life-saving treatments.

By working closely with academic, research and NHS institutions, MedCity aims to stimulate an interconnected region for life sciences research, development, manufacturing and commercialisation, which will subsequently bring about greater economic growth and improvements to public health. Together we invite our colleagues across the globe to collaborate with industry and academia within the region to help drive forward future neuroscience innovations.

Read our report on the neuroscience research across the Golden Triangle region: http://www.medcityhq.com/wp-content/uploads/2017/04/neurodegen-single-V2.pdf